SCHEMBL22570013

SCHEMBL22570013

c1ccc(CNc2ncnn3c([C@@H]4O[C@H](COCc5ccccc5)[C@@H](OCc5ccccc5)[C@H]4OCc4ccccc4)ccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.41
▸ BCHE P06276 1/20 0.36
▸ PTPN1 P18031 9/20 0.36
▸ CDC25B P30305 8/20 0.36
▸ PTPN2 P17706 5/20 0.36
▸ PTPN6 P29350 4/20 0.36
▸ PTPN11 Q06124 4/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ PDE2A O00408 1/20 0.35
▸ NT5E P21589 1/20 0.35
▸ TACR2 P21452 2/20 0.34
▸ SSTR1 P30872 1/20 0.34
▸ SSTR2 P30874 1/20 0.34
▸ SSTR4 P31391 1/20 0.34
▸ SSTR3 P32745 1/20 0.34
▸ SSTR5 P35346 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19343920 0.90 HTR1A (0.41) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL19101893 0.85 BCHE (0.40) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL29937871 0.85 HTR1A (0.43) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL29937393 0.85 HTR1A (0.43) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL25598746 0.85 HTR1A (0.43) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL17106818 0.85 HTR1A (0.43) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL17106820 0.85 HTR1A (0.43) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL17106778 0.82 HTR1A (0.41) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL22002160 0.82 HTR1A (0.41) HTR1ABCHEPTPN1CDC25BPTPN2
SCHEMBL17106780 0.82 HTR1A (0.41) HTR1ABCHEPTPN1CDC25BPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204539-A1 CD73 INHIBITORS BIOARDIS LLC 2022-06-30 — — US disclosed
US-20220204539-A1 CD73 INHIBITORS BIOARDIS LLC 2022-06-30 — — US disclosed
WO-2020210970-A1 IMIDAZOTRIAZINE DERIVATIVES AS CD73 INHIBITORS BIOARDIS LLC (US) 2020-10-22 — — WO disclosed
WO-2020211672-A1 CD73 INHIBITORS BIOARDIS LLC (US) 2020-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204539-A1 CD73 INHIBITORS ENTPD5, ENTPD1, ENTPD2 HTR1A 2118/4885BCHE 663/4885PTPN1 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback